SU5416 (Semaxanib): Selective VEGFR2 Tyrosine Kinase Inhibitor for Angiogenesis and Immune Modulation

Executive Summary: SU5416 (Semaxanib) is a selective inhibitor of the VEGFR2 (Flk-1/KDR) tyrosine kinase, potently blocking VEGF-induced angiogenesis in vitro and in vivo (DOI). It also acts as an aryl hydrocarbon receptor (AHR) agonist, modulating immune pathways via IDO induction. The compound demonstrates effective inhibition of VEGF-driven mitogenesis at an IC₅₀ of 0.04±0.02 μM in HUVEC cells (37°C, standard culture media). SU5416 (SKU A3847) by APExBIO is widely adopted in cancer research for suppressing tumor vascularization and is validated in mouse xenograft models at 1–25 mg/kg/day without observed dose-limiting toxicity. Its solubility profile (≥11.9 mg/mL in DMSO) and defined storage/workflow parameters enable reproducible results in angiogenesis and immune modulation assays (APExBIO product page).

Biological Rationale

Vascular endothelial growth factor (VEGF) signaling via VEGFR2 is essential for physiological and pathological angiogenesis. Aberrant activation of VEGFR2 promotes endothelial proliferation, new vessel formation, and supports tumor growth (Neelakantan et al., 2025). Inhibition of VEGFR2 disrupts these processes, making it a central target in anti-angiogenic cancer therapies. SU5416 (Semaxanib) selectively targets the Flk-1/KDR (VEGFR2) receptor tyrosine kinase, blocking downstream pathways critical for endothelial survival and proliferation. Additionally, SU5416 acts on the aryl hydrocarbon receptor (AHR), influencing immune cell differentiation and tolerance mechanisms via induction of indoleamine 2,3-dioxygenase (IDO) (internal review).

Mechanism of Action of SU5416 (Semaxanib) VEGFR2 inhibitor

SU5416 (Semaxanib) is a synthetic small molecule designed to competitively inhibit ATP binding at the catalytic domain of VEGFR2 (Flk-1/KDR) tyrosine kinase. This inhibits VEGF-induced autophosphorylation and blocks activation of downstream effectors such as PLCγ, MAPK, and PI3K/AKT pathways. The result is suppression of endothelial cell proliferation, migration, and tube formation. In addition, SU5416 acts as an agonist of the aryl hydrocarbon receptor (AHR), leading to upregulation of IDO and modulation of regulatory T cell (Treg) differentiation, implicating a role in immune tolerance and suppression of inflammatory responses (more on immune modulation).

Evidence & Benchmarks

• SU5416 inhibits VEGF-driven mitogenesis in HUVEC cells with an IC₅₀ of 0.04±0.02 μM under standard in vitro conditions (37°C, 5% CO₂, serum-containing media) (APExBIO product page).
• It suppresses tumor vascularization and growth in mouse xenograft models when administered intraperitoneally at 1–25 mg/kg daily, with no observed treatment-related mortality at the upper dose limit (Neelakantan et al., 2025).
• SU5416 is insoluble in ethanol and water but highly soluble in DMSO (≥11.9 mg/mL at 25°C), allowing for concentrated stock solutions and consistent dosing (APExBIO).
• In vivo, SU5416 has been validated to induce pulmonary arterial remodeling in rodent models of pulmonary hypertension, enabling study of vascular resistance and compliance mechanisms relevant to right ventricular afterload (DOI).
• As an AHR agonist, SU5416 upregulates IDO expression, promoting regulatory T cell differentiation in autoimmune and transplant tolerance models (internal review).

This article extends the practical workflow and mechanistic details found in SU5416 (Semaxanib) VEGFR2 inhibitor: Scenario-Driven Solutions by providing updated, quantitative benchmarks and clarifying immune modulation mechanisms. For more on atomic mode-of-action and efficacy, see Atomic Mechanism & Benchmarks; this article integrates those insights with translational and workflow-focused perspectives.

Applications, Limits & Misconceptions

SU5416 (SKU A3847) is widely used in cancer research as an angiogenesis inhibitor and in studies dissecting vascular remodeling in pulmonary hypertension. Its action as an AHR agonist expands utility to immune modulation, including models of autoimmunity and transplant tolerance. However, its specificity for VEGFR2 means it is not a pan-tyrosine kinase inhibitor. Efficacy is context-dependent, with optimal results in settings where VEGF/VEGFR2 signaling is the primary driver of pathology. For cytotoxicity and viability assay best practices, see Scenario-Driven Best Practices—this article clarifies compound-specific integration and boundaries.

Common Pitfalls or Misconceptions

• SU5416 does not inhibit all VEGF receptors; it is selective for VEGFR2 (Flk-1/KDR).
• It is not effective as a direct cytotoxin; anti-tumor effects are due to angiogenesis inhibition, not direct killing of tumor cells.
• SU5416 is insoluble in water or ethanol; improper solvent use leads to precipitation and inconsistent dosing.
• Use outside validated dose ranges (above 25 mg/kg i.p. in mice) may result in off-target effects or toxicity not reported in published studies.
• Immune modulation effects (via AHR/IDO) are cell- and context-dependent and may not be observed in all models.

Workflow Integration & Parameters

For in vitro studies, prepare stock solutions in DMSO (≥11.9 mg/mL), warming to 37°C or sonicating to ensure complete dissolution. Store aliquots at -20°C for up to several months. Typical working concentrations range from 0.01 to 100 μM. For in vivo work (e.g., xenograft mouse models), intraperitoneal administration at 1–25 mg/kg/day is recommended, with no mortality observed at upper limits under standard conditions. Use of vehicle controls (DMSO in saline or appropriate buffer) is essential for reproducibility. For detailed protocol contrasts and troubleshooting, consult Strategic Frontiers in Angiogenesis and Immune Modulation, which this article updates with storage and workflow specifics validated for SKU A3847 from APExBIO.

Conclusion & Outlook

SU5416 (Semaxanib) is a validated, selective VEGFR2 inhibitor with defined efficacy in angiogenesis inhibition, tumor vascularization suppression, and immune modulation via AHR. Its robust solubility in DMSO and stable storage profile enable reproducible results in both in vitro and in vivo systems. As angiogenesis and immune modulation remain key frontiers in cancer and vascular biology, SU5416 (A3847) by APExBIO is positioned as a reference tool for mechanistic, preclinical, and translational research. Future directions include integration with multi-targeted anti-angiogenic regimens and expanding its use in immune tolerance models. For full technical details and ordering, refer to the SU5416 (Semaxanib) VEGFR2 inhibitor product page.